Larimar Therapeutics, Inc.
LRMR
$0.03
Change (1 day)
$13.68
Year High
$3.01
Year Low
Categories
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Revenue of Larimar Therapeutics, Inc. (LRMR)
Revenue in 2023 (TTM): $
According to Larimar Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Larimar Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-311,000 | $-41,447,000 | $-36,949,000 | $-36,949,000 |
| 2022 | $ | $-272,000 | $-35,083,000 | $-35,355,000 | $-34,184,000 |
| 2021 | $ | $-326,000 | $-50,139,000 | $-50,636,000 | $-50,310,000 |
| 2020 | $ | $-155,000 | $-42,649,000 | $-42,482,000 | $-42,327,000 |
| 2019 | $ | $-78,000 | $-23,136,000 | $-23,132,000 | $-23,132,000 |
| 2018 | $ | $-261,000 | $-60,809,000 | $-62,968,000 | $-61,368,000 |
| 2017 | $ | $-188,000 | $-52,575,000 | $-52,928,000 | $-52,028,000 |
| 2016 | $ | $-212,000 | $-57,437,000 | $-58,178,000 | $-57,878,000 |
| 2015 | $ | $-70,000 | $-73,410,000 | $-74,286,000 | $-74,286,000 |
| 2014 | $ | $ | $-35,532,000 | $-36,570,000 | $-36,570,000 |
| 2013 | $ | $-12,000 | $-14,015,000 | $-14,027,000 | $-14,027,000 |
| 2012 | $ | $-11,000 | $-13,772,000 | $-13,880,000 | $-13,880,000 |
| 2011 | $ | $-4,000 | $-13,153,000 | $-13,157,000 | $-13,157,000 |